We need a range of treatments to make Covid-19 preventable and treatable. Jeremy Farrar describes recent progress made by research and why more investment is needed.
Monoclonal antibodies, one of the most promising treatments for Covid-19, are usually expensive and not available worldwide. Lindsay Keir highlights what needs to be done to change that.
We know that in the charity sector it can be difficult for colleagues to challenge bad practice. That’s why we’ve developed Speak Up – a new initiative to help us build a real culture of trust.
For more than 30 years, monoclonal antibodies have transformed the way we treat many diseases. Researchers think they are also one of the most promising treatments for Covid-19. Here's why.
Six months after lockdown was first announced in the UK, the country is seeing a rise in Covid-19 infections. Jeremy Farrar reflects on the measures we need to suppress transmission.
Wellcome launched COVID-Zero in April to mobilise urgent donations from businesses and philanthropists for Covid-19 research. As we draw the campaign to a close, Mark Henderson discusses what it has achieved.
Covid-19 is exacerbating existing health, economic and social inequalities in the US and across the world. Claude Lopez explains why investing in coronavirus treatment research and development is an imperative for business leaders and philanthropists.
The Covid-19 pandemic is a social and an economic crisis just as much as it is a health crisis – its repercussions, severe and far-reaching, are being felt across the world.
We need to understand the impact of Covid-19 on wider health issues to shape better public health responses and limit long-term consequences. Drug resistance is one of these, Gemma Buckland-Merrett explains.
The world is waiting eagerly for Covid-19 vaccines to be developed as quickly as possible. But to make sure they are safe and effective, the clinical trials that test them have to be robust. So how do trials achieve this?
As we'll soon start to see the results of the first vaccines coming through late-stage clinical trials, Jeremy Farrar explains why we should be cautiously optimistic.